Stem cell therapy in Mexico: what patients from the US and Canada need to know before making a decision

Thousands of patients in North America seeking stem cell treatments travel to Mexico each year to receive MSC therapy that they cannot access at home. A factual analysis of why—and how to navigate it safely.

Mesenchymal stem cell therapy has a strong clinical evidence base, a growing patient population, and clear demand—yet virtually no legal pathway for most patients in the United States or Canada to access it. That gap, not the price, is driving one of the most significant medical travel patterns in North America right now.

This article explains that gap precisely: what the actual regulatory situation is in each country, why cost structures differ the way they do, what the science says, and—most importantly—what a patient evaluating this treatment should ask before booking anything.

1. The regulatory landscape: why access is limited at home

To understand why patients travel, it is necessary to understand what is and is not legally available in their countries of origin and why.

In the United States, the FDA approved its first mesenchymal stem cell therapy in December 2024: Ryoncil (remestemcel-L), authorized exclusively for pediatric patients with steroid-resistant acute graft-versus-host disease (GvHD). That is the full scope of FDA-approved MSC therapy as of 2026.

All other applications, such as joint injections for osteoarthritis, IV infusions for autoimmune conditions, and longevity protocols, are classified as investigational.

The mechanism behind this restriction is specific. Culture-expanded allogeneic MSCs are regulated as biologic drugs under Section 351 of the Public Health Service Act. They require a Biologics License Application (BLA), a process that costs between one and two billion dollars per indication and takes a decade or more. No MSC product for orthopedic or longevity use has yet passed that threshold.

The practical consequence for patients: most US clinics offering stem cell therapy can only work with autologous cells—those taken from the patient's own bone marrow or fat tissue—which circumvents the biologics approval requirement. These cells are as biologically old as the patient, have reduced regenerative capacity compared to younger donor cells, and produce a lower yield, limiting dosage.

The situation in Canada is even more restrictive. Health Canada classifies all cell therapies as drugs under the Food and Drug Act. Only remestemcel-L for GvHD has received marketing authorization. The agency has issued formal public warnings about unauthorized clinics operating in the country. For orthopedic, autoimmune, or longevity indications, legally available MSC therapy simply does not exist in Canada.

Mexico took a different regulatory path. In 2012, COFEPRIS—the Federal Commission for Protection against Sanitary Risks—established a licensing framework that allows clinics to offer culture-expanded allogeneic MSC therapy under defined quality and oversight requirements. Clinics must have a specific Cell Therapy License, verifiable in a public registry. Manufacturing laboratories must comply with Good Manufacturing Practices (GMP) standards. The framework does not declare MSC therapy categorically safe; it creates a supervised pathway for its use.

Country	Regulator	MSC therapy status (2026)	Allogeneic access
USA	FDA	One approval (pediatric GvHD only)	Not available
Canada	Health Canada	One approval (GvHD only)	Not available
European Union	EMA	Last authorized product recalled in Dec. 2024	Not available
Mexico	COFEPRIS	Licensing framework since 2012	Available (licensed clinics)

2. What science says

Mesenchymal stem cells are multipotent stromal cells found in bone marrow, adipose tissue, the umbilical cord, and the placenta. They do not primarily function by replacing damaged tissue. The current understanding is that they act largely through paracrine signaling—releasing growth factors, cytokines, and extracellular vesicles that modulate inflammation, suppress immune overactivation, and create conditions for the body's own repair mechanisms to function more effectively.

For orthopedic indications, particularly knee osteoarthritis, the evidence is stronger. A 2023 meta-analysis published in Stem Cell Reviews and Reports, which analyzed 18 randomized controlled trials, found statistically significant improvements in pain scores and functional outcomes at 12 months in patients treated with MSCs compared to controls. The effects were more pronounced in younger patients and those with earlier-stage disease. Attenuation was observed at 24 months, suggesting that MSC therapy functions more as a disease-modifying intervention than a permanent structural solution.

For systemic indications—autoimmune conditions, long-term COVID sequelae, and longevity protocols—the evidence base is more nascent. Phase I and II trials have demonstrated acceptable safety profiles in several indications, but large-scale randomized controlled trials are lacking. The evidence at this time does not support broad clinical claims, but neither does it support dismissing the therapeutic potential.

What the evidence clearly supports is this: not all MSC preparations are equivalent. The cell source, donor age, expansion conditions, dosage, route of administration, and patient indication all affect outcomes in ways that make provider quality a direct clinical variable, not merely a consumer preference.

3. Autologous vs. allogeneic cells: why the distinction matters

This is probably the most crucial variable a patient needs to understand before evaluating any clinic, because it determines what type of cells they will actually receive — and most providers don't proactively explain this.

Autologous therapy

Autologous MSCs are obtained from the patient's own body—typically through bone marrow aspiration from the hip or liposuction of adipose tissue. The procedure avoids the risk of immune rejection. However, the cells are as biologically old as the patient. The proliferative capacity, secretory activity, and differentiation potential of MSCs decline measurably with age. A 65-year-old patient receiving their own cells is receiving 65-year-old cells. The yield is also limited by what the body produces at harvest, which restricts the dosage.

Allogeneic therapy

Allogeneic MSCs are derived from a carefully selected young donor—typically umbilical cord tissue, Wharton's jelly, or placental tissue obtained at birth. These cells maintain a high proliferative capacity, can be expanded in culture to achieve precise dose targets, and are considered immunoprivileged due to the low expression of surface markers that trigger rejection responses. The biological rationale for young donor cells is well established; the practical barrier in the United States is regulatory, not scientific.

Most US clinics offer autologous therapy specifically because expanded allogeneic stem cells require BLA approval, which they lack. This limitation is not a clinical preference—it is a regulatory restriction. The COFEPRIS framework in Mexico permits both approaches under quality supervision, which is why the allogeneic option is available in licensed Mexican clinics but not in most US clinics.

4. Costs: what patients actually pay, and why

The price ranges for MSC therapy are broad and often misrepresented. The figures below are drawn from clinic-published price pages, the BioInformant 2026 cost report, and the Bookimed database, which covers 704 verified clinics. They represent mid-range estimates for providers with documented quality standards—not necessarily the cheapest option available in every market.

Type of treatment	Typical US range	Mexico (licensed clinics)	Insurance coverage
Joint injection (simple)	$5,000 – $10,000 USD	$2,500 – $6,500 USD	None in any country
Systemic IV infusion	$15,000 – $30,000 USD	$4,500 – $9,500 USD	None in any country
Combined protocol	$25,000 – $50,000 USD	$6,500 – $14,000 USD	None in any country

Insurance coverage is worth clarifying: US private insurers, Medicare, and Canadian provincial plans classify MSC therapy for orthopedic, autoimmune, and longevity indications as experimental. Treatment is out-of-pocket regardless of jurisdiction. This means that the relevant comparison for an international patient is the total cash cost—including travel.

A patient traveling from the U.S. East Coast to Mexico City should budget approximately $650 USD for round-trip flights and $1,800 USD for five nights in a quality hotel near the clinic. Even with those costs included, the total is typically 50 to 60% lower than a comparable provider in the U.S. — assuming that provider could offer allogeneic stem cells, which most cannot.

The price gap is structural, not a sign of lower quality. Four factors explain most of it:

• 1 Regulatory costs

  US clinics that operate off-label also charge institutional review costs, enhanced malpractice coverage, and compliance infrastructure that are passed on to fees even for cash-paying patients.

  
  

• 2 Malpractice insurance

  Annual malpractice premiums for U.S. regenerative medicine specialists routinely exceed $40,000–$100,000 USD per physician. Equivalent coverage in Mexico costs a fraction of that amount—a structural difference unrelated to the quality of care.

  
  

• 3 Real Estate and Operation

  Class A medical real estate in Los Angeles, Miami, or New York costs multiples of the equivalent space in Mexico City. Physician and nurse salaries, while competitive in absolute terms, reflect local market rates.

  
  

• 4 Administrative expenses

  Administrative costs for healthcare in the US represent approximately 8% of total healthcare spending, compared to the OECD average of 3%. Billing and pre-authorization fees are factored into clinic prices even for procedures not covered by insurance.

  
  

5. How to evaluate a clinic — anywhere

The variability in quality among MSC providers in Mexico is significant. The regulatory framework establishes a minimum standard; it does not guarantee that all licensed clinics operate to the same standard. These are the specific questions a patient should ask before committing to any provider—and the answers that should emerge without questioning a reliable one.

About this article: This article was written by the medical team at Lonvida. Lonvida is a COFEPRIS-licensed regenerative medicine clinic in Polanco, Mexico City (Cell Therapy License No. 25-TR-09-016-0001). We have a vested interest in patients choosing our clinic and have tried to write this article in a way that is helpful regardless of where the patient decides to go. If you find any factual errors or outdated information, please contact us.

• Verify the COFEPRIS Cell Therapy License number in the public registry. Request the number and look it up yourself at cofepris.gob.mx . This takes less than two minutes and is the most basic due diligence available to an international patient. A legitimate clinic will provide the number without you having to ask.

• Request the manufacturing laboratory's GMP certification separately. The clinic license and the laboratory's GMP certification are different documents. The laboratory must operate under ISO 5/6/7/8 cleanroom standards. Ask for the laboratory's name and its certification—not just a statement that it is certified.

• Request a Certificate of Analysis (CoA) for your specific cell lot. This document must show the cell count, viability (target ≥95%), sterility test results, mycoplasma testing, endotoxin levels, and flow cytometry markers that confirm MSC identity: CD73+, CD90+, CD105+, CD34−, CD45−. A clinic that cannot produce this document is not operating with traceability.

• Ask to speak with the doctor who will oversee your treatment before booking. The treatment plan should be based on your individual medical history and a previous diagnosis—not a standardized package. If you can't reach the treating physician before committing, that's a significant red flag about how the clinic operates.

• Ask about follow-up care after you return home. MSC therapy is not a one-time transaction with guaranteed results. A provider who doesn't offer structured follow-up isn't treating you—they're selling you a procedure.

"The question to ask is not 'Is this clinic cheaper?' but 'Can this clinic show me the documentation that any credible MSC provider anywhere in the world should be able to produce?'" Dr. María José Pardinas, Medical Director, Lonvida

7. What to do with this information

The regulatory gap between what patients in the US and Canada can access in their countries and what is available in Mexico is not going to close anytime soon. BLA approvals for MSC therapies are progressing, but the timeline makes widespread domestic access a decades-long prospect for most indications.

Meanwhile, patients evaluating MSC therapy do so in a market with wide variance in quality and limited protection from regulatory institutions in their home countries. This doesn't make the option inadvisable—it simply shifts more of the due diligence burden onto the patient than would be the case in a domestic setting.

The framework for this due diligence is not complicated. Verify the license. Confirm the laboratory. Request the Certificate of Analysis. Speak with the doctor before committing. Ask about follow-up care. A clinic that meets these five criteria is operating to a standard that gives you a reasonable basis for making an informed decision. One that cannot meet them, regardless of its online presence, is not.

About this article: This article was written by the medical team at Lonvida. Lonvida is a COFEPRIS-licensed regenerative medicine clinic in Polanco, Mexico City (Cell Therapy License No. 25-TR-09-016-0001). We have a vested interest in patients choosing our clinic and have tried to write this article in a way that is helpful regardless of where the patient decides to go. If you find any factual errors or outdated information, please contact us.

The allogeneic cell therapies described here are not FDA-approved and are administered exclusively in accordance with Mexican regulations. This content does not constitute medical advice. Individual results vary. Consult a qualified physician before making any treatment decisions.

Sources: US FDA (Ryoncil approval letter, December 2024); Health Canada, Cell Therapy Guide (2024); EMA (Alofisel withdrawal, December 2024); COFEPRIS, Health Supplies Regulation, Title 14 (2012); ISSCR Guidelines for Stem Cell Research and Clinical Translation (2024); Pas HH et al., Stem Cell Reviews and Reports (2023); BioInformant Stem Cell Therapy Cost Report 2026; Bookimed database, 704+ verified clinics (January 2026); Placidway US MSC Price Guide 2025.